(5alpha,6beta)-17-(2-Phenylethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride (1:1)(CAS: 5013-01-4)

(5alpha,6beta)-17-(2-Phenylethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride is a crystalline compound with a molecular weight of approximately 454.45 g/mol. It is slightly soluble in water and ethanol. The compound is relatively stable under normal conditions but may hydrolyze in strongly acidic or basic environments. It is used in pharmaceutical applications and exhibits good solubility in organic solvents like dimethyl sulfoxide (DMSO).

(5alpha,6beta)-17-(2-Phenylethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride is typically synthesized via a multistep process involving epoxidation of a morphinan derivative followed by coupling with a phenylethyl chloride. The synthesis often requires the use of catalysts such as titanium tetrachloride and is performed under anhydrous conditions. Yield is generally around 70-80%, with good selectivity for the desired product.

(5alpha,6beta)-17-(2-Phenylethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride is primarily used in the pharmaceutical industry for the development of analgesic and antitussive drugs. It is also explored for its potential in sensor technologies and as a component in certain polymer formulations.

(5alpha,6beta)-17-(2-Phenylethyl)-4,5-epoxymorphinan-3,6,14-triol hydrochloride should be handled in a well-ventilated area, preferably under a fume hood. PPE such as gloves and safety glasses should be worn. Spills should be contained and disposed of according to local regulations. Always refer to the Safety Data Sheet (SDS) for detailed handling and storage instructions.